Citations

Clear

6 citation(s) found for "Schreiber, Martin".

Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Bioengineered Human Arteries for the Repair of Vascular Injuries in an Extremity Injury Subset of Trial Participants
Moore, Ernest E. , Kundi, Rishi, Rajani, Ravi R. , Sokolov, Oleksandr , Niklason, Laura E. , Khondker, Zakaria, Parikh, Shamik , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Brenner, Megan , Lum, Ying Wei, Namias, Nicholas, Fujitani, Roy M. , Magee, Gregory A. , Batista, Philip M. , Trani, Jose, Oresanya, Lawrence , Sjoholm, Lars Ola, Calero, Aurelia, Seamon, Mark J. , Malas, Mahmoud B. , Clouse, Darrin, Naslund, Thomas C., Callcut, Rachael A. , Grandas, Oscar H., Skarupa, David , Southerland, Kevin W. , Freeman, Carl, Hurie, Justin , Goldin, Ilya, Karram, Tony, Greenberg, George, Halak, M., Skupyy, Oleh, Yurets, Serhii, Stanko, Oleksandr , Curi, Michael A. , Namias, Nicholas , Kundi, Rishi, Lum, Ying Wei , Fox, Charles J. , Rasmussen, Todd E. , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Morrison, Jonathan J. , Lum, Ying Wei, Shores, Jaimie T. , Namias, Nicholas, Schreiber, Martin J. , Halak, Moshe, Shaprynskyi, Vasyl V.

Mayo Clinic

JAMA Surgery | November 20, 2024 | Volume: 160 | Issue: 2 | Pages: 181

10.1001/jamasurg.2024.4893 | PMID 39565635 Get It

Importance Vascular injuries require urgent repair to minimize loss of limb and life. Standard revascularization relies on autologous vein or synthetic grafts, but alternative options are needed when adequate vein is not feasible and when clinical conditions preclude safe use of synthetic materials. Objective To evaluate the performance of the acellular tissue engineered vessel (ATEV) in the repair of extremity arterial injuries. Design, Setting, and Participants Two open-label, single-arm, nonrandomized clinical trials, including 1 prospective civilian study (CLN-PRO-V005 [V005]) and 1 retrospective observational study in a war zone (CLN-PRO-V017 [V017]), were conducted from September 2018 to January 2024 (follow-up ongoing) at 19 level 1 trauma centers in the US and Israel and 5 frontline hospitals in Ukraine. Patients had vascular injury, no autologous vein available for emergent revascularization, and risk factors for wound infection. Data include the subset of patients with extremity injuries and were analyzed from September 2023 to January 2024. Intervention The ATEV is a bioengineered vascular conduit grown from human vascular cells, available off the shelf, and implantable without immunosuppression. Main Outcomes and Measures Primary patency at day 30 was the primary outcome. Secondary outcomes included limb salvage, graft infection, and patient survival. A systematic literature review identified synthetic graft benchmarks in the treatment of arterial trauma for the same end points. Results The arterial extremity injury subset included 51 of 69 participants in V005 and 16 of 17 participants in V017. The majority were male (V005, 38 [74.5%]; V017, 16 [100%]), the mean (SD) ages were similar (V005, 33.5 [13.6] years; V017, 34.2 [9.0] years), and the mean (SD) Injury Severity Scores were similar (V005, 20.8 [10.5]; V017, 20.1 [18.9]). Penetrating injuries dominated (V005, 29 patients [56.9%]; V017, 14 patients [87.5%]). At day 30 for the V005 and V017 trials, respectively, ATEV primary patency was 84.3% (95% CI, 72.0%-91.8%) and 93.8% (95% CI, 71.7%-98.9%); secondary patency was 90.2% (95% CI, 79.0%-95.7%) and 93.8% (95% CI, 71.7%-98.9%); amputation rate was 9.8% (95% CI, 4.3%-21.0%) and 0% (95% CI, 0.0%-19.4%); ATEV infection rate was 2.0% (95% CI, 0.4%-10.3%) and 0% (95% CI, 0.0%-19.4%); and death rate was 5.9% (95% CI, 2.0%-15.9%) and 0% (95% CI, 0.0%-19.4%) (no deaths attributed to the ATEV at day 30). Day 30 synthetic graft benchmarks were as follows: secondary patency, 78.9%; amputation, 24.3%; infection, 8.4%; and death, 3.4%. Conclusions and Relevance Results of analysis in the subset of patients with vascular extremity injuries in 2 single-arm trials in civilian and real-world military settings suggest that the ATEV provides benefits in terms of patency, limb salvage, and infection resistance. Comparing ATEV outcomes with synthetic graft benchmarks demonstrated improved outcomes in the treatment of acute vascular injuries of the extremities. The analyses reported herein are limited to the subset of 67 patients with vascular extremity injuries out of 86 patients enrolled in 2 trials and excluded 19 patients with iatrogenic and torso injuries. Had these 19 patients been included in these analyses, the efficacy and safety findings could have been attenuated. Trial Registration ClinicalTrials.gov Identifiers: NCT03005418 , NCT05873959
Civilian walking blood bank emergency preparedness plan
Holcomb, John B. , Spinella, Philip C. , Apelseth, Torunn Oveland , Butler, Frank K., Cannon, Jeremy W. , Cap, Andrew P., Corley, Jason B., Doughty, Heidi , Fitzpatrick, Michael H., Goldkind, Sara F., Gurney, Jennifer M. , Homer, Mary J. , Jenkins, Donald H. , Moore, Eugene, Ness, Paul M., Schreiber, Martin A. , Shinar, Eilat , Sloan, Steve, Stubbs, James R. , Taylor, Audra L., Ward, Kevin R. , Waltman, Elizabeth, Yazer, Mark H. , Jansen, Jan O , Strandenes, Geir , Stubbs, James R , Yazer, Mark , Spinella, Philip C , Apelseth, Torunn , Holcomb, John B , Cap, Andrew P., Ilstrup, Sarah J. , Jansen, Jan O. , Marques, Marisa B. , O’Connor, Kevin C. , Strandenes, Geir

Mayo Clinic

Transfusion | July 16, 2021 | Volume: 61 | Issue: S1 | Pages: No page available

10.1111/trf.16458 | PMID 34269450 Get It

Abstract Background The current global pandemic has created unprecedented challenges in the blood supply network. Given the recent shortages, there must be a civilian plan for massively bleeding patients when there are no blood products on the shelf. Recognizing that the time to death in bleeding patients is less than 2 h, timely resupply from unaffected locations is not possible. One solution is to transfuse emergency untested whole blood (EUWB), similar to the extensive military experience fine‐tuned over the last 19 years. While this concept is anathema in current civilian transfusion practice, it seems prudent to have a vetted plan in place. Methods and Materials During the early stages of the 2020 global pandemic, a multidisciplinary and international group of clinicians with broad experience in transfusion medicine communicated routinely. The result is a planning document that provides both background information and a high‐level guide on how to emergently deliver EUWB for patients who would otherwise die of hemorrhage. Results and Conclusions Similar plans have been utilized in remote locations, both on the battlefield and in civilian practice. The proposed recommendations are designed to provide high‐level guidance for experienced blood bankers, transfusion experts, clinicians, and health authorities. Like with all emergency preparedness, it is always better to have a well‐thought‐out and trained plan in place, rather than trying to develop a hasty plan in the midst of a disaster. We need to prevent the potential for empty shelves and bleeding patients dying for lack of blood.
Prophylactic Drainage after Appendectomy for Perforated Appendicitis in Adults: A Post Hoc Analysis of an EAST Multi-Center Study
Qian, Sinong , Vasileiou, Georgia , Pust, Gerd Daniel , Zakrison, Tanya L. , Rattan, Rishi , Zielinski, Martin D. , Ray-Zack, Mohamed D. , Group, on behalf of the EAST Appendicitis Study, Alouidor, Reginald, Hing, Kailyn Kwong, Sharp, Victoria , Serena, Thomas , Kasotakis, George , Perez, Sean, Allmond, Stacie L., Long, Bruce, Barth, Nadine, Roman, Janika San, Lawless, Ryan A. , Cralley, Alexis , Gelbard, Rondi B. , Szczepanski, Crystal, Eyer, Steven D., Proulx, Kaitlyn, Wild, Jeffrey, Young, Katelyn , Teicher, Erik J. , Lita, Elena, Morris, David S. , Juarez, Laura, Catalano, Richard D., Turay, David, Roberts, Jennifer C., Kaafarani, Haytham M.A., Eid, Ahmed , Kanaan, Tala , Portillo, Victor, Collom, Morgan, Eddine, Savo Bou Zein , Tabrizi, Maryam B. , Elsharkawy, Ahmed Elsayed Mohammed , Yeh, D. Dante, Evans, David , Vázquez, Daniel , Saxe, Jonathan M. , Jacobson, Lewis E. , Behrens, Brandon, Joseph, Bellal , Mull, Jennifer, Pasley, Jason, O’Meara, Lindsay , Gök, Ali , To, Jocelyn, Bradley, Matthew J. , Zielinski, Martin, Zeeshan, Muhammad , Namias, Nicholas , Yeh, D. Dante , Group, on behalf of the EAST Appendicitis Study, Morris, David, Cullinane, Daniel C. , Roberts, Jennifer C., Dodgion, Christopher M. , Yeh, D. Dante, Vazquez, Daniel E., Schreiber, Martin J. , Nahmias, Jeffry T. , Sun, Beatrice J. , Crandall, Marie , Rodríguez, Carlos

Mayo Clinic

Surgical Infections | April 20, 2021 | Volume: 22 | Issue: 8 | Pages: 780-786

10.1089/sur.2019.258 | PMID 33877912 Get It